Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Emory University Millennium Pharmaceuticals, Inc. |
---|---|
Information provided by: | Emory University |
ClinicalTrials.gov Identifier: | NCT00634179 |
This is an open-label (doctors and patients know which drug will be given), single center, phase 1/2 clinical trial. The primary objective is to determine whether VR-CHOP provides benefit to patients with previously untreated indolent non-Hodgkin's lymphomas (NHL).
Condition | Intervention | Phase |
---|---|---|
Lymphoma, B-Cell Follicular Lymphoma |
Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, bortezomib, prednisone |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas |
Estimated Enrollment: | 39 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | February 2087 |
Estimated Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
This is an open-label, single-center, prospective phase 1/2 clinical trial with a dose escalation and de-escalation schema for bortezomib and vincristine to identify the maximum tolerated doses (MTD) of bortezomib and vincristine when used in a chemotherapy regimen consisting of VELCADE and R-CHOP.In phase 2, the trial will evaluate the efficacy and safety of the MTD combination of VELCADE and rituximab-CHOP in additional subjects. At the start of phase 1, treatment will consist of rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 given on day 1, bortezomib 1.3 mg/m2 given on days 1 and 8, and prednisone 100 mg/day given orally on days 1-5. Dose titration will occur in the phase 1 portion to a maximum bortezomib dose of 1.6 mg/m2 given on days 1 and 8 followed by titration of the vincristine dose to 1.4 mg/m2. |
Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, bortezomib, prednisone
rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 (capped at 1.5 mg maximum) given on day 1, bortezomib 1.3 mg/m2 given on days 1 and 8, and prednisone 100 mg/day given orally on days 1-5.
|
This study will assess whether adding Velcade to R-CHOP (in a new combination called VR-CHOP) can further improve outcomes in patients with indolent NHL who have not previously received treatment. Patients who are eligible to take part in the study will initially receive VR-CHOP with an increase in the dose of Velcade and then the dose of vincristine to determine the safe doses for these drugs in combination. Then, patients will receive VR-CHOP for up to 8 cycles of treatment (each of 21 days duration). During treatment, patients will be assessed for their response to therapy and for possible side effects.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with follicular or other low-grade lymphoma must have an indication for treatment based on modified GELF criteria or a FLIPI score
Exclusion Criteria:
United States, Georgia | |
Emory University Winship Cancer Institute | Recruiting |
Atlanta, Georgia, United States, 30322 | |
Contact: Christopher Flowers, MD, MS 888-946-7447 | |
Principal Investigator: Christopher Flowers, MD | |
Emory University Winship Cancer Institute | Recruiting |
Atlanta, Georgia, United States, 30322 | |
Contact: Christopher Flowers, MD, MS 888-946-7447 |
Principal Investigator: | Christopher Flowers, MD | Emory University |
Responsible Party: | Winship Cancer Institute ( Christopher Flowers, MD ) |
Study ID Numbers: | IRB# 29960007 |
Study First Received: | February 11, 2008 |
Last Updated: | May 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00634179 History of Changes |
Health Authority: | United States: Institutional Review Board |
Lymphoma |
Anti-Inflammatory Agents Prednisone Immunologic Factors Hormone Antagonists Lymphoma, Follicular Hormones, Hormone Substitutes, and Hormone Antagonists Cyclophosphamide Follicular Lymphoma Hormones Lymphoma, B-Cell Anti-Bacterial Agents Lymphoma Alkylating Agents Immunoproliferative Disorders Antineoplastic Agents, Hormonal |
Rituximab Bortezomib Vincristine Antimitotic Agents Immunosuppressive Agents Glucocorticoids Doxorubicin Protease Inhibitors Lymphatic Diseases B-cell Lymphomas Tubulin Modulators Antineoplastic Agents, Alkylating Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Antirheumatic Agents |
Anti-Inflammatory Agents Prednisone Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Lymphoma, Follicular Cyclophosphamide Antibiotics, Antineoplastic Hormones Lymphoma, B-Cell Therapeutic Uses Lymphoma Alkylating Agents |
Immunoproliferative Disorders Neoplasms by Histologic Type Antineoplastic Agents, Hormonal Immune System Diseases Rituximab Mitosis Modulators Bortezomib Vincristine Enzyme Inhibitors Antimitotic Agents Glucocorticoids Immunosuppressive Agents Doxorubicin Pharmacologic Actions Protease Inhibitors |